73 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B Uptrend
Article Searches
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
Big Bristol-Myers Shareholder Opposes Celgene Deal https://www.wsj.com/articles/big-bristol-myers-shareholder-opposes-celgene-deal-11551310954?mod=pls_whats_news_us_business_f Feb 27, 2019 - One of Bristol-Myers’s largest shareholders is opposing the company’s $74 billion deal to buy rival Celgene, becoming the latest investor to express its unhappiness with the transaction.
3 Best Biotech Bargain Stocks on the Market Right Now https://www.fool.com/investing/2019/03/05/3-best-biotech-bargain-stocks-on-the-market-right.aspx?source=iedfolrf0000001 Mar 05, 2019 - If you're looking to buy biotech stocks on the cheap, these three could be right up your alley.
Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat http://www.zacks.com/stock/news/358423/celldex-cldx-q4-loss-narrower-than-expected-sales-beat?cid=CS-ZC-FT-358423 Mar 08, 2019 - Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-ZC-FT-359854 Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/359869/mercks-keytruda-gets-eu-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-359869 Mar 15, 2019 - Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle? https://www.fool.com/investing/2019/03/19/starboard-vs-bristol-myers-squibb-and-celgene-whol.aspx?source=iedfolrf0000001 Mar 19, 2019 - An activist investor made a strong argument for walking away from Celgene, but will investors listen?
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/361461/roches-tecentriq-gets-fda-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-361461 Mar 19, 2019 - Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/363083/why-bristol-myers-squibb-bmy-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-363083 Mar 22, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Celgene (CELG) Submits NDA for MS Drug to FDA for Review http://www.zacks.com/stock/news/365034/celgene-celg-submits-nda-for-ms-drug-to-fda-for-review?cid=CS-ZC-FT-365034 Mar 26, 2019 - Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.

Pages: 123456...8

Page 1>